Wuhan Hiteck Biological Pharma Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 19.96%

Wuhan Hiteck Biological Pharma Co Ltd (300683) has an Asset Resilience Ratio of 19.96% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥526.22 Million

≈ $77.00 Million USD Cash + Short-term Investments

Total Assets

CN¥2.64 Billion

≈ $385.87 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2019–2024)

This chart shows how Wuhan Hiteck Biological Pharma Co Ltd's Asset Resilience Ratio has changed over time. Check Wuhan Hiteck Biological Pharma Co Ltd strategic capital allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Wuhan Hiteck Biological Pharma Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Wuhan Hiteck Biological Pharma Co Ltd worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥526.22 Million	19.96%
Total Liquid Assets	CN¥526.22 Million	19.96%

Asset Resilience Insights

Good Liquidity Position: Wuhan Hiteck Biological Pharma Co Ltd maintains a healthy 19.96% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Wuhan Hiteck Biological Pharma Co Ltd Industry Peers by Asset Resilience Ratio

Compare Wuhan Hiteck Biological Pharma Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Takeda Pharmaceutical Company Limited F:TKDA	Drug Manufacturers - Specialty & Generic	0.69%
Shandong Buchang Pharmaceuticals Co Ltd SHG:603858	Drug Manufacturers - Specialty & Generic	3.47%
Beijing Sun Novo Pharmaceutical Research Co Ltd SHG:688621	Drug Manufacturers - Specialty & Generic	2.04%
Guizhou Xinbang Pharmaceutical Co Ltd SHE:002390	Drug Manufacturers - Specialty & Generic	0.01%
Guangdong Lifestrong Pharmacy Co. Ltd. SHE:301111	Drug Manufacturers - Specialty & Generic	7.85%
Jw Pharmac KO:001060	Drug Manufacturers - Specialty & Generic	3.65%
Kamada TA:KMDA	Drug Manufacturers - Specialty & Generic	0.00%
Samjin Pharm KO:005500	Drug Manufacturers - Specialty & Generic	0.25%

Annual Asset Resilience Ratio for Wuhan Hiteck Biological Pharma Co Ltd (2019–2024)

The table below shows the annual Asset Resilience Ratio data for Wuhan Hiteck Biological Pharma Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	15.31%	CN¥449.69 Million ≈ $65.80 Million	CN¥2.94 Billion ≈ $429.72 Million	+15.30pp
2023-12-31	0.01%	CN¥303.97K ≈ $44.48K	CN¥2.97 Billion ≈ $434.79 Million	-5.31pp
2022-12-31	5.32%	CN¥144.04 Million ≈ $21.08 Million	CN¥2.71 Billion ≈ $396.03 Million	-13.75pp
2021-12-31	19.07%	CN¥514.40 Million ≈ $75.27 Million	CN¥2.70 Billion ≈ $394.73 Million	+7.62pp
2020-12-31	11.45%	CN¥250.39 Million ≈ $36.64 Million	CN¥2.19 Billion ≈ $319.96 Million	-10.65pp
2019-12-31	22.11%	CN¥479.57 Million ≈ $70.18 Million	CN¥2.17 Billion ≈ $317.47 Million	--

pp = percentage points

About Wuhan Hiteck Biological Pharma Co Ltd

SHE:300683 China Drug Manufacturers - Specialty & Generic

Market Cap

$489.96 Million

CN¥3.35 Billion CNY

Market Cap Rank

#12181 Global

#3493 in China

Share Price

CN¥25.58

Change (1 day)

-0.74%

52-Week Range

CN¥23.33 - CN¥59.41

All Time High

CN¥84.19